Surgical Options for Optic Disc Pit Maculopathy: Perspectives and Controversies

Abstract: Optic disc pit (ODP) is a rare congenital optic nerve head abnormality, which can be complicated by intraretinal and subretinal fluid at the macula (ODP-macularopathy) with progressive visual loss. The source of this fluid remains unclear and the most dominant hypotheses have pointed to vitreous cavity or cerebrospinal fluid. Although spontaneous resolution has been reported, the majority of untreated cases of ODP-macularopathy result in final visual acuity less than 20/200 or worse. A wide array of interventions, either individually or in combination with adjuvant treatments, have been tried with varying degrees of success. Recently, different surgical procedures to fill the ODP by self-sealing materials in combination with pars plana vitrectomy have been reported as an effective adjuvant treatment. However, given the relative rarity of this condition, the majority of reports describe a small retrospective case series, making it difficult to compare among different treatments options and create a consensus regarding the optimal treatment for ODP-macularopathy. In this situation, a mini-review about surgical treatment modalities and their results can be a useful approach to identify the most effective surgical option in the management of ODP-macularopathy.

Keywords: optic disc pit, optic disc pit maculopathy, optic disc pit maculopathy treatments, optic nerve stuffing, post-operative outcomes, pars plana vitrectomy

Introduction

Optic disc pit (ODP) is considered to be part of the spectrum of rare congenital cavitary abnormalities of the optic disc, occurring in the majority of the cases on the temporal side of the optic disc.\(^1\) It is usually unilateral, sporadic in occurrence and can occur equally in men and women with an estimated prevalence of 1 out of 10,000 people.\(^2\)

In the absence of other sequelae, many of the patients may remain asymptomatic and it may be found incidentally. Sometimes, the symptoms are generally limited to arcuate scotomas or enlargement of the blind spot in visual field tests.\(^2-4\) However, when ODP is complicated by maculopathy (ODP-M), it may cause significant visual deterioration. ODP-M is the term used to describe the existence of intraretinal and subretinal fluid at the macula as well as retinal pigment changes. It can occur in up to 25–75% of all cases.\(^2-5\) Regarding the pathophysiology of ODP-M and the origin of fluid, the exact mechanism remains unclear. It has been proposed that either vitreous or cerebrospinal fluid (CSF) may be responsible for macular detachment in eyes with ODP.\(^6-8\)

When ODP-M is present, visual acuity (VA) is usually affected to 20/70 or worse,\(^2,5,9-13\) but in the untreated and long-standing cases, which can be associated with cystoid changes, lamellar or full-thickness macular holes, and retinal pigment detachment.
epithelium (RPE) atrophy, the visual impairment is usually irreversible, leading to a reduced VA to 20/200 or worse in the affected eye. 2,5,9-13 Therefore, interventions are valuable, as they may prevent significant visual loss in these patients. However, despite the improved insight into this unusual pathology, currently, there is no consensus regarding its optimal treatment. Maybe because the nature and the origin of the fluid causing the macular detachment are still controversial with no known triggers. 2,5,9-13 The purpose of this mini-review is to discuss the possible surgical treatments options and the postoperative outcomes data of this challenging entity.

**Conservative Management**

In the management of ODP-M, especially in pediatric cases, a spontaneous resolution with an improvement of visual acuity is possible. 14,15 Therefore, a more conservative approach with 3–6 months of follow-up before any surgical procedure could be appropriate. However, it must be kept in mind that the number of pediatric cases is small, relapses are frequent, and the prognosis remains poor in approximately 25% to 75% of the patients.2-5

Since patients with ODP may remain asymptomatic with normal visual acuity until 2nd to 4th decades of life2-5 an individualized approach should be considered in each case assessing the visual symptoms with the clinical and imaging findings, but currently, in the presence of progression of fluid accumulation and/or visual loss, observation is deemed unjustified. 5,13

**Surgical Treatment Options**

Currently, there is no optimal accepted treatment for ODP-M because the pathogenesis of the disease is not yet fully understood. However, since vitreous traction, specifically the vitreopapillary traction, 2,5,16-18 has been suggested to play an important role in the pathogenesis of ODP-M, pars plana vitrectomy (PPV) with the induction of posterior vitreous detachment (PVD) remains the most widely accepted treatment of choice for this entity. 6,9-13,19-22 Tight vitreous attachment over the optic nerve has been reported in previous studies preoperatively by OCT and intraoperatively by iOCT in ODP-M patients. 16,17,23 Therefore, inducing a PVD by PPV can relieve the traction exerted by the vitreous on either the macula or the ODP, facilitating the absorption of subretinal fluid. Most of the published literature on ODP-M is focused on PPV techniques which have evolved along with the breakthroughs. 2,5,9-13 A summary of some published series of PPV and adjuncts treatments for ODP-M is given in Table 1.

A wide array of adjuvant treatments, including injection of gas, 20,21,24,25 air, 17 or silicone tamponade, 26 juxta-papillary laser, 20,24,27 retinal fenestration, 28 glial tissue removal 29 and macular internal limiting membrane (ILM) peeling, 25,27,30 in combination with PPV have been tried with varying degrees of success.

The majority of these studies reported high anatomical success rates (50% to 95%) and similar functional results, with VA improvement in >50% of cases in routine cases. 9,13,17,20,24-27,31,32 However, these adjuvant interventions are not exempt from risks and complications whilst successfully long-term anatomical results have been achieved with just PPV alone. 19-22

In cases where a vitreous substitute is necessary, the use of gas would be a reasonable approach to prevent the migration into the brain or subretinal space. 26,33-36 Thus, avoiding the use of perflurocarbon liquid or silicone oil because of their lower surface tension and easier migration. Also, migration of gas is much less problematic and easy to manage than silicone oil or heavy liquid migration.

Temporal endolaser photocoagulation has been proposed as a treatment for ODP-M, 20,24,27 with the reasoning that laser scars will act as a “permanent” barrier to prevent fluid from leaking into the macula. However, this method of treatment can cause significant visual field defects because of the damage over the maculopapular bundle. 24,30,37 Furthermore, it has been reported that laser treatment does not aid in anatomical success. 19,27,38 Peeling the ILM in these cases may result in a high incidence of macular hole creation, as well as anatomical changes of the macula including dimpling or damage to the inner retina. 39 In addition, there are numerous surgical series showing excellent results without ILM peeling. 23,25,40,41 Thus, this maneuver seems to be questionable and probably not essential in the treatment of most cases of ODP-M. Creation of an inner retinal fenestration or glial tissue removal, 29 procedures that involve risk of optic nerve injury, fall short of providing adequate evidence to be recommended for ODP-M, as they did not show an increment in the surgical success rate.

Therefore, if the vitreous cavity is the source of the fluid in ODP-M, then the role of PPV + induction of PVD would be the most reasonable and effective treatment, as the adjuvant procedures may not confer any tangible added benefit over PPV alone. 19-22

However, this vitreous traction hypothesis has some limitations as it cannot explain the recurrent cases of
Table 1 Main Recent Series Describing Treatment for Optic Disc Pits with Maculopathy

| Study [Ref.]               | Cases, n | Main Surgery with/ Without Adjuvant Techniques | Main Results                                                                 | Effect of the Adjuvant Treatment |
|----------------------------|----------|-----------------------------------------------|------------------------------------------------------------------------------|---------------------------------|
| Avci et al 2017            | 51 eyes  | 20 G, 23 G, 25 G, TA, EL, ILM-P, C2F8, SF6    | 58.8% showed CR within 6 months, while 25.5% resolved at month 12 and thereafter CR with no further treatments: 86.3% | No significant effect of EL, ILM-P, C2F8 or SF6 on the final success rate |
| Bottconi et al 2018        | 11 eyes  | 20 G, 25 G, TA, EL, ocriplasmin, SF6          | The macular detachment resolved within a mean of 14 months after surgery CR with no further treatments: 80% | No significant effect of EL, ocriplasmin or SF6 on the final success rate |
| Rayat et al 2015           | 32 eyes  | 20 G, 23 G, 25 G, TA, EL, ILM-P, C2F8, SF6    | The median time to reattachment was 416 days CR with no further treatments: 80.3% | No significant effect of EL, ILM-P, C2F8 or SF6 on the final success rate |
| Aboammeh et al 2016        | 46 eyes  | 20 G, 23 G, 25 G, TA, EL, ILM-P, C2F8, SF6    | The mean time to resolution was 12.1±10.6 months for all eyes CR with no further treatments: 72% | No significant effect of EL, ILM-P, C2F8 or SF6 on the final success rate |
| Teke and Ciritik 2015      | 17 eyes  | 23 G, TA, EL, C2F8                            | The mean time to reattachment was (20.9)±3.2 months in the adjuvant group and 25.5±4.0 months in the group with PPV alone CR with no further treatments: 7% | No significant effect of EL or C2F8 on the final success rate |
| Hirakata et al 2012        | 8 eyes   | 20 G, 25 G, TA                                | Up to about 1 year for retinal detachment resolution CR with no further treatments: 88% | Gas tamponade does not seem to be crucial Lack of a control group |
| Nadal et al 2015           | 19 eyes  | 20 G, 23 G, TA, APC, C2F8                     | Retinal fluid reabsorption within a median of 3.5 months CR with no further treatments: 100% | APC and C2F8 are highly effective alternative techniques, but a control group was lacking |
| Avci et al 2013            | 13 eyes  | 23 G, TA, EL, C2F8                            | Fluid reabsorption by month 12 (84.6%) CR with no further treatments: 92% | ILM may not be required for anatomical success Lack of a control group |
| Gregory-Roberts et al 2013 | 9 eyes   | ? G, forceps for glial tissue, EL, gas        | CR with no further treatments: 89% | Higher rate of CR when glial tissue was removed, but a control group was lacking |
| Kiang and Johnson 2017     | 11 eyes  | ? G, previous laser treatment, EL, gas        | The average time to macular fluid resolution was 8.5 months CR with no further treatments: 100% | 2 eyes required additional treatment Secondary approach if vitrectomy alone fails Absence of a control group |
| Pastor-Idoate et al 2019   | 9 eyes   | 23 G, 25 G, TA, EL, I-ILM, C2F8              | The mean duration of preoperative symptoms was 422 days Retinal fluid reabsorption in 56% at 6 months | Residual postoperative ILM fragments (78%) Laser and gas do not seem to be crucial Secondary approach in chronic/recurrent cases Lack of a control group |
| Ghosh et al 2008           | 7 eyes   | ? G, EL, air, SO, SF6, C2F8                   | The duration of their symptoms was between 2 weeks in a child to 5 months in an elderly man. CR with no further treatments: 100% | 4 eyes required additional treatment Lack of a control group |
| Ooto et al 2014            | 18 eyes  | 23 G, 25 G, fenestration                     | The macular detachment decreed within a mean of 6.1 months CR with no further treatments: 94% | Spontaneous closure in the early postoperative period, suggesting no significant effect Lack of a control group |
| Theodossiadis and           | 23 eyes  | SB                                            | The macular reattachment was noticed between 6 and 12 months CR with no further treatments: 85% | Intraoperative B scan required Satisfactory long-term results Lack of a control group |
| Theodossiadis, Chatziralli, and Theodossiadis 2015 | 12 eyes  | SB                                            | The mean followed up was 12.8±1.5 years after the surgical intervention with successful anatomical and functional results | No cataract induction during the follow-up period. Lack of a control group |

(Continued)
neither it can explain the ODP-M cases developed in patients with total PVD.

But if the source of the fluid is the CSF, then further explanation regarding the efficacy of PPV is needed.\textsuperscript{42} Maybe in those cases, the key point for obtaining a successful surgery could be the emergence of recent adjuvant treatments that are principally focused on sealing the pit. The justification for sealing the ODP with different materials such as ILM flap (Figure 1),\textsuperscript{14,41–46} fibrin glues\textsuperscript{47,48} or autologous fibrin,\textsuperscript{49} homologous scleral tissue\textsuperscript{50} or even silicone lacrimal plug,\textsuperscript{51} is based on the recent hypothesis postulated by Jain and Johnson,\textsuperscript{7} in which different pressure ranges between the eye and intracranial pressure can lead to migration of fluid from the vitreous cavity or CSF to intraretinal or subretinal space due to a defect either in the lamina cribrosa or the juxtapapillary area.\textsuperscript{7} Therefore, from a theoretical point of view, a procedure to create a “broad plug” along the “involved” disc margin could prevent the translaminar difference of pressure or block the outflow of fluids to the retinal layers or subretinal space.

Table 1 (Continued).

| Study [Ref.] | Cases, n | Main Surgery with/ Without Adjuvant Techniques | Main Results | Effect of the Adjuvant Treatment |
|--------------|----------|-----------------------------------------------|-------------|---------------------------------|
| Lei et al 2015\textsuperscript{42} | 9 eyes | C\textsubscript{3}F\textsubscript{8}, LT | The period required for complete reattachment was 6–18 months. Complete retinal reattachment was achieved in seven out of nine eyes | Repeat treatment was required in 5 eyes with complete treatment in 3 eyes. Lack of a control group. |
| Akiyama et al 2014\textsuperscript{43} | 8 eyes | SF\textsubscript{6} | The period required for reattachment after final gas treatment was 12 months. The mean number of gas injections was 1.8 CR with no further treatments: 50% | Secondary approach if intravitreal gas injection alone fails. Absence of a control group. |

Notes: Presented are only studies that included more than 7 patients with optic disc pits with maculopathy. *Treatment without vitrectomy; ?, no data available. 
Abbreviations: APC, autologous platelet concentrate; C\textsubscript{3}F\textsubscript{8}, perfluoropropane; CR, complete resolution; EL, endolaser; LT, laser photocoagulation; G, gauge; I–ILM, inverted internal limiting membrane; ILM-P, internal limiting membrane peeling; PPV, pars plana vitrectomy; SF\textsubscript{6}, sulphur hexafluoride; SB, scleral buckling; SO, silicone oil; TA, triamcinolone acetonide assisted.

Figure 1 (A) Preoperative OCT image showing the anatomic features of an ODP and the associated maculopathy. The translaminar defect which can lead to migration of fluid (arrow) from the vitreous cavity or CSF to intraretinal or subretinal space. (B and C) Intraoperative vertical and horizontal OCT scans through the optic disc showing the ILM flap “sealing” the ODP (white arrows).

Abbreviations: OCT, optical coherence tomography; ODP, optic disc pit; CSF, cerebrospinal fluid; ILM, internal limiting membrane.
However, even though reports describe successful anatomical and functional results that have been maintained long term in some cases, the restricted number of cases and low level of evidence limit the use of these methods.\(^9\)\(^{-14}\)\(^{41}\)\(^{-51}\)

Our experience using the ILM flap technique in nine consecutive patients suggested a moderate rate of anatomical success, as 44% of our patients remained with unattached macula even 6 months after the surgery.\(^14\) However, published studies\(^44\),\(^45\) using the same technique have reported quick improvements and promising functional outcomes. Such differences might be related to the reduced function of the retinal pigment epithelium-Bruch’s membrane complex, as well as by degeneration within the retinal layers in chronic and/or refractory macular detachment patients.\(^30\),\(^50\)

In some of these patients, we have observed a relapse. However, in those refractory cases, we have considered preferable to apply for another novel technique initially described by Travassos et al\(^50\) in which autologous scleral graft is used for sealing the pit with good initial outcomes (Figure 2).

The concept of these techniques would consist of covering the optic disc, including the ODP, creating a barrier to the fluid passage from the pit to the macular region. Although both techniques have demonstrated favorable long-term results, the use of ILM or scleral flap may be beneficial only in selected cases of optic pit maculopathy. However, the evidence remains low and more studies are warranted.

One of the main concerns that should be addressed in the future is the potential damage to the optic nerve and neurosensory retina caused by surgical trauma and/or the cytotoxicity of introducing different sealing materials into the ODP, as the majority of results are presented without visual field tests or macular sensitivity tests.\(^14\)

**Other Techniques**

Pneumatic tamponade with or without laser photocoagulation is another therapeutic option for ODP-M.\(^52\) Theoretically, this dual treatment could ensure the induction of PVD, alleviating the vitreous tractions and facilitating the reattachment of the macula, and the formation of a barrage to seal the passage between the ODP and the macula.\(^53\) However, this technique has only reported retinal reattachment in approximately 50% of cases. Additionally, significant visual field defects and no improvement in VA have been reported after peripapillary barrier with photocoagulation.\(^2\),\(^5\),\(^7\)

Macular buckling (MB) is another alternative for ODP-M and it has been reported a success rate of about 85%

---

**Figure 2** (A) Preoperative horizontal OCT scan through the optic disc and fovea, showing an abundance of subretinal macular fluid, extending towards the ODP as well as subretinal hyperreflective deposits suggesting a long-standing case. (B) Intraoperative fundus picture showing the autologous scleral plugging into the ODP. (C) Postoperative follow-up image showing foveal re-attachment with no evidence of subretinal fluid but with residual local alterations at the interdigitation and ellipsoid zones.  
**Abbreviations:** OCT, optical coherence tomography; ODP, optic disc pit.
with long-term visual improvement and low rates of complications or recurrences.\textsuperscript{42,54–56} The macular buckle pushes the macular surface toward the vitreous cavity, preventing the entrance of fluid and alleviating vitreous tractions. It is worthy to note that MB seems to provide favorable results independently of the origin of the fluid in ODP-M. However, MB is considered a difficult and demanding technique and, for this reason, is not widely applied nowadays.\textsuperscript{9–13}

**Conclusions**

ODP is a rare disease, and most of them are diagnosed incidentally.\textsuperscript{1,2,9–13} In patients with ODP-M, the prognosis is relatively poor, leading to visual loss in the untreated cases.\textsuperscript{2,9–13} In addition, the origin of the macular fluid and its triggers have yet to be understood. This lack of clarity has spawned a diversity of pathophysiology theories and treatment approaches with variable efficacy.\textsuperscript{9–13}

Compared to other indications for vitreoretinal surgery, there is no established guideline for the treatment of ODP-M, neither is there a consensus on the most effective surgical technique.\textsuperscript{9–13} Additionally, the majority of the proposed adjuvant surgical techniques are challenging to perform. Convenience and comfort zones may affect the choice of treatment. Table 1 depicts the main treatment modalities for ODP-maculaopathy.

Most of the reports about adjuvant treatments for ODP-M describe successful anatomical and functional results that have been maintained long term with a very low rate of recurrence and with very few postoperative complications in routine cases.\textsuperscript{9–13} However, limited experience exists for these alternative interventions and further studies are required to confirm these preliminary outcomes.

However, there is still a paucity of literature on the management of chronic and/or refractory cases, in which their outcomes may be limited by reduced function of RPE-Bruch’s membrane complex, photoreceptor apoptosis or by retinal layers’ degeneration. Most of the reports document the visual and anatomical improvements during the first two postoperative years. This is very important to the appropriate setting of patients’ expectations prior to surgery.

Certainly, the best clinical evidence to determine which treatment is superior in ODP-M patients should be obtained through a randomized clinical trial of different adjuvant surgical techniques to PPV. However, it is unlikely that such a trial can be performed as this is a very rare clinical entity.\textsuperscript{9–13}

Nowadays, the gold standard for the treatment of ODP-M is still the PPV and PVD induction.\textsuperscript{9–13,19–22} Adjuvant procedures in combination with PPV are several and varied but they would probably be pertinent when the primary surgery fails.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Gowdar JP, Rajesh B, Giridhar A, Gopalakrishnan M, Hussain R, Thachil T. An insight into the pathogenesis of Optic disc pit-associated maculopathy with enhanced depth imaging. *JAMA Ophthalmol.* 2015;133(4):466–469. doi:10.1001/jamaophthalmol.2014.6903

2. Georgalas I, Ladas I, Georgopoulos G, Petrou P. Optic disc pit: a review. *Graefe’s Arch Clin Exp Ophthalmol.* 2011;249(8):1113–1122. doi:10.1007/s00417-011-1698-5

3. Brodsky M, Baker R, Hamed L. Pediatric Neuro-Ophthalmology. 2nd ed. New York: Springer; 2010.

4. Tawara A, Miyamoto R, Tou N, Ishibashi S, Kondo H. A classic temporal optic disc pit showing progression in the corresponding optic nerve fiber and visual field defects. *Jpn J Ophthalmol.* 2013;57(3):263–267. doi:10.1007/s10384-012-0225-5

5. Shah SD, Yee KK, Fortun JA, Albini T. Optic disc pit maculopathy: a review and update on imaging and treatment. *Int Ophthalmol Clin.* 2014;54(2):61–78. doi:10.1097/IIO.0000000000000025

6. Irvine AR, Crawford JB, Sullivan JH. The pathogenesis of retinal detachment with morning glory disc and optic pit. *Retina.* 1986;6(3):146–150. doi:10.1097/00006982-198606030-00002

7. Jain N, Johnson MW. Pathogenesis and treatment of maculopathy associated with cavitary optic disc anomalies. *Am J Ophthalmol.* 2014;158(3):423–435. doi:10.1016/j.ajo.2014.06.001

8. Sugar HS. An explanation. For the acquired macular pathology associated with congenital pits of the optic disc. *Am J Ophthalmol.* 1964;57(5):833–835. doi:10.1016/0002-9394(64)90225-4

9. Sobol WM, Blodi CF, Folk JC, Weingeist TA. Long-term visual outcome in patients with optic nerve pit and serous retinal detachment of the macula. *Ophthalmology.* 1990;97(11):1539–1542. doi:10.1016/S0161-6420(90)32380-1

10. Uzel MM, Karacorlu M. Optic disc pits and optic disc pit maculopathy: a review. *Surv Ophthalmol.* 2019;64(5):595–607. doi:10.1016/j.survophthal.2019.02.006

11. Chatziralli I, Theodossiadis P, Theodossiadis GP. Optic disc pit maculopathy: current management strategies. *Clin Ophthalmol.* 2018;12:1417–1422. doi:10.2147/OPHT.S153711

12. Moisseiev E, Moisseiev J, Loewenstein A. Optic disc pit maculopathy: when and how to treat? A review of the pathogenesis and treatment options. *Int J Retina Vitreous.* 2015;1(1):1–9. doi:10.1186/s40942-015-0013-8

13. Kalogeropoulos D, Ch’ng SW, Lee R, et al. Optic disc pit maculopathy: a review. *Asia Pac J Ophthalmol.* 2019;8(3):247–255. doi:10.22608/ypo.2018473

14. Yuen CHW, Kaye SB. Spontaneous resolution of serous maculopathy associated with optic disc pit in a child: a case report. *J AAPOS.* 2002;6(5):330–331. doi:10.1067/mao.2002.127921

15. Bayar SA, Sezenöz AS, Pinarcı EY, Yılmaz G. Spontaneous regression of optic disc pit maculopathy in a six-year-old child. *Turk Oftalmoloji Derg.* 2017;47(1):56–58. doi:10.4274/toj.57614

16. Pastor-Idoate S, Gómez-Resa M, Karam S, et al. Efficacy of internal limiting membrane flap techniques with vitrectomy for macular detachment associated with an optic disc pit. *Ophthalmologica.* 2019;242(1):38–48. doi:10.1159/000495621
51. Deltour JB, Masse H, Lebreton O, Weber M. Successful use of a silicone lacrimal plug to treat a case of refractory macular detachment associated with a large optic disc pit. *Acta Ophthalmol.* 2020;98(1):e126–e127. doi:10.1111/aos.14116

52. Lei L, Li T, Ding X, et al. Gas tamponade combined with laser photocoagulation therapy for congenital optic disc pit maculopathy. *Eye.* 2015;29(1):106–114. doi:10.1038/eye.2014.245

53. Akiyama H, Shimoda Y, Fukuchi M, et al. Intravitreal gas injection without vitrectomy for macular detachment associated with an optic disc pit. *Retina.* 2014;34(2):222–227. doi:10.1097/IAE.0b013e3182993d93

54. Georgopoulos GT, Theodossiadis PG, Kolias A-C, Vergados J, Patsea EE, Theodossiadis GP. Visual field improvement after treatment of optic disk pit maculopathy with the macular buckling procedure. *Retina.* 1999;19(5):370. doi:10.1097/00006982-199909000-00001

55. Theodossiadis GP, Theodossiadis PG. The macular buckling technique in the treatment of optic disc pit maculopathy. *Semin Ophthalmol.* 2000;15(2):108–115. doi:10.3109/08820530009040001

56. Theodossiadis GP, Theodossiadis PG. Optical coherence tomography in optic disk pit maculopathy treated by the macular buckling procedure. *Am J Ophthalmol.* 2001;132(2):184–190. doi:10.1016/S0002-9394(01)00997-7